This is a StreetInsider.com Premium Only Page

(DMAC) – Press Releases

Apr 17, 2024 04:08 PM DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke

Mar 19, 2024 04:15 PM DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results

Jan 29, 2024 04:13 PM DiaMedica Therapeutics Announces Poster Presentation at International Stroke Conference

Jan 22, 2024 08:23 AM DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer

Nov 13, 2023 04:28 PM DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial Results

Nov 9, 2023 08:25 AM DiaMedica Therapeutics to Attend the 14th Annual Craig-Hallum Alpha Select Conference November 16, 2023

Nov 6, 2023 08:23 AM DiaMedica Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update November 14, 2023

Sep 12, 2023 08:13 AM DiaMedica Therapeutics Announces the Appointment of Ambarish Shah, Ph.D. as Chief Technology Officer

Sep 6, 2023 08:35 AM DiaMedica Therapeutics to Participate at Lake Street’s 7th Annual Best Ideas Growth Conference

Aug 14, 2023 04:13 PM DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2023 Financial Results

Aug 8, 2023 08:32 AM DiaMedica Therapeutics to Report Second Quarter 2023 Financial Results and Provide a Business Update August 15, 2023

Jul 18, 2023 08:30 AM DiaMedica Therapeutics to Attend the American Academy of Neurology Summer Conference

Jun 26, 2023 08:30 AM DiaMedica Therapeutics Announces Closing of $37.5 Million Private Placement

Jun 21, 2023 08:39 AM DiaMedica Therapeutics Announces $37.5 Million Private Placement

Jun 21, 2023 08:15 AM DiaMedica Therapeutics Announces that the FDA Has Removed The Clinical Hold On DM199 Phase 2/3 Trial For Ischemic Stroke

May 30, 2023 08:29 AM DiaMedica Therapeutics Announces Appointment of Dr. Richard Kuntz to the Board of Directors

May 15, 2023 04:28 PM DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2023 Financial Results

May 8, 2023 08:50 AM DiaMedica Therapeutics to Report First Quarter 2023 Financial Results and Provide a Business Update May 16, 2023

Apr 11, 2023 08:41 AM DiaMedica Therapeutics Appoints David Wambeke as Chief Business Officer

Mar 28, 2023 04:30 PM DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2022 Financial Results

Mar 20, 2023 04:17 PM DiaMedica Therapeutics to Report Fourth Quarter 2023 Financial Results and Provide a Business Update March 29, 2023

Mar 13, 2023 08:00 AM DiaMedica Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference

Mar 6, 2023 08:30 AM DiaMedica Therapeutics Announces the Appointment of Biopharma Veteran Tanya Lewis to Its Board of Directors

Nov 9, 2022 04:15 PM DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2022 Financial Results

Nov 7, 2022 08:32 AM DiaMedica Therapeutics to Attend the 13th Annual Craig-Hallum Alpha Select Conference November 17, 2022

Oct 31, 2022 08:32 AM DiaMedica Therapeutics to Present at Credit Suisse 31st Annual Healthcare Conference

Oct 26, 2022 04:30 PM DiaMedica Therapeutics Provides Update on ReMEDy2 Trial

Sep 14, 2022 08:30 AM DiaMedica Therapeutics Appoints Julie Daves as SVP, Clinical Development Operations

Sep 6, 2022 04:10 PM DiaMedica Therapeutics to Present at Lake Street’s 6th Annual Best Ideas Growth Conference

Aug 10, 2022 05:20 PM DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2022 Financial Results

Aug 4, 2022 08:12 AM DiaMedica Therapeutics to Report Second Quarter 2022 Financial Results and Provide a Business Update August 11, 2022

Aug 1, 2022 04:32 PM DiaMedica Therapeutics to Participate in the BTIG Biotechnology Conference 2022

Jul 6, 2022 04:41 PM DiaMedica Therapeutics Announces Clinical Hold of its Phase 2/3 ReMEDy2 Clinical Trial for DM199

Jun 17, 2022 07:00 AM Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders and Appoints James T. Parsons to its Board of Directors

May 25, 2022 04:15 PM DiaMedica Therapeutics to Attend the 19th Annual Craig-Hallum Institutional Investor Conference Wednesday, June 1, 2022

May 4, 2022 04:32 PM DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2022 Financial Results

Apr 28, 2022 08:15 AM DiaMedica Therapeutics to Report First Quarter 2022 Financial Results and Provide a Business Update May 5, 2022

Mar 14, 2022 04:45 PM DiaMedica Therapeutics Provides a Business Update and Announces Fourth Quarter 2021 Financial Results

Mar 8, 2022 08:13 AM DiaMedica Therapeutics to Report Fourth Quarter 2021 Financial Results and Provide a Business Update March 15, 2022

Feb 2, 2022 08:43 AM DiaMedica Therapeutics Announces Appointment of Dominic Cundari as Chief Commercial Officer

Jan 25, 2022 08:43 AM DiaMedica Therapeutics to Present Research at International Stroke Conference

Jan 5, 2022 08:40 AM DiaMedica Therapeutics Appoints Dr. Kirsten Gruis as Chief Medical Officer

Dec 13, 2021 08:23 AM DiaMedica Therapeutics Announces Participation in LifeSci Partners 11th Annual Corporate Access Event

Nov 17, 2021 08:23 AM DiaMedica Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

Nov 10, 2021 04:35 PM DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2021 Financial Results

Nov 9, 2021 04:07 PM DiaMedica Therapeutics to Attend the 12th Annual Craig-Hallum Alpha Select Conference November 16, 2021

Nov 8, 2021 08:35 AM DiaMedica Therapeutics Announces Addition of Stroke Recurrence as a Second Independent Primary Endpoint in ReMEDy2 Phase 2/3 AIS Trial

Nov 4, 2021 08:30 AM DiaMedica Therapeutics to Report Third Quarter 2021 Financial Results and Provide a Business Update November 11, 2021

Oct 18, 2021 08:30 AM DiaMedica Therapeutics Announces Late Breaking Data from REDUX Phase 2 Trial to be Presented at ASN Kidney Week 2021

Sep 30, 2021 08:45 AM DiaMedica Therapeutics Announces Fast Track Designation Granted to DM199 for the Treatment of Acute Ischemic Stroke